CYTOKINETICS INCORPOR

Cytokinetics Reports Second Quarter 2022 Financial Results

04 8月 2022 16:00:00 条件 Nasdaq GlobeNewswire

Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials

04 8月 2022 07:30:01 条件 Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 8月 2022 16:00:00 条件 Nasdaq GlobeNewswire

Cytokinetics to Announce Second Quarter Results on August 4, 2022

21 7月 2022 16:00:00 条件 Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

05 7月 2022 16:00:00 条件 Nasdaq GlobeNewswire

Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering

01 7月 2022 03:35:20 条件 Nasdaq GlobeNewswire

Cytokinetics Announces Proposed Convertible Senior Notes Offering

29 6月 2022 16:35:18 条件 Nasdaq GlobeNewswire

Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil

24 6月 2022 07:30:00 条件 Nasdaq GlobeNewswire

Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil

17 6月 2022 07:30:00 条件 Nasdaq GlobeNewswire

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

16 6月 2022 07:30:00 条件 Nasdaq GlobeNewswire